SecBot SecBot
8-K ·Filed Aug 10, 2026

OLMA

Olema Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001193125-26-342334
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock's next major catalyst is the Phase 3 OPERA-01 top-line data in Q1 2027. Monitor upcoming clinical data at medical meetings and any initiation of the Bayer collaboration Phase 1b/2 study in Q4 2026 for potential incremental catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

OLMA drug pipeline →

palazestrant

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.
Next catalyst
None dated

What to watchThe next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.

Price Chart

Loading chart...

Executive Summary

Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025, driven by increased R&D spend on late-stage trials for palazestrant (OPERA-01) and the advancement of OP-3136. The company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027, and ended the quarter with a strong cash position of $461.1M. The wider loss and lack of revenue keep the stock binary on the upcoming Phase 3 data readout.

Key Financial Metrics

EPS
−$0.61
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Net loss for Q2 2026 was $63.2 million, compared to $43.8 million in Q2 2025.
  • Completed enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant; top-line data expected Q1 2027.
  • Cash, cash equivalents, and marketable securities totaled $461.1 million as of June 30, 2026.
  • GAAP R&D expenses increased to $57.8 million from $43.9 million year-over-year.
  • Announced a clinical trial collaboration with Bayer to evaluate OP-3136 in combination with darolutamide.
  • Net loss per share for Q2 2026 was $(0.61), compared to $(0.51) in Q2 2025.

Financial Impact

Net loss widened by $19.4 million year-over-year; cash position decreased by $44.4 million from year-end 2025.

net lossR&D expensescash & equivalents

Risk Factors

  • Phase 3 OPERA-01 top-line data may fail to meet endpoints, destroying value.
  • Cash burn is significant at $63.2M per quarter, potentially requiring future dilutive financing before a potential launch.
  • Pipeline is binary on palazestrant; early-stage OP-3136 has no near-term data readout.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342334
Document: olma-20260810.htm0001193125-26-342334
Document: 0001193125-26-342334-index-headers.html0001193125-26-342334
Document: 0001193125-26-342334-index.html0001193125-26-342334
Document: 0001193125-26-342334.txt0001193125-26-342334
8-K Data (Synthetic)0001193125-26-342334

Track record

20 reports on OLMA

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
  3. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
  4. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
  5. Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
  7. Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
  8. Aug 10, 202614w ago 8-K Neutral 5/10 Viewing No price data
  9. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
  10. Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026